Dermata soars as psoriasis treatment found safe, effective in study

Dermata Therapeutics

18/10/2021 22:32

** Shares of drug developer  DRMA.O  soar 22.7% to $5.40 in
extended trading
    ** Dermata Therapeutics reports positive topline results
from an early stage study testing its lead drug candidate,
DMT310, as a once-weekly topical treatment for mild-to-moderate
psoriasis, a chronic skin disease (https://bit.ly/3C6gYDy)
    ** Treatment with DMT310 helped reduce severity of the
disease as well as demonstrated reduction in severe itching at
week 8 - co
    ** Says drug appeared to be safe with only three reported
adverse events, none of which were serious
    ** Based on results, co plans to continue study of DMT310 in
psoriasis
    ** Up to last close, DRMA had fallen 15.2% since its market
debut on Aug 13

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))